Heart & lung : the journal of critical care · 2025
Prognostic role of neutrophil-lymphocyte glycemic index in patients with pulmonary embolism.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saribas Mehmet Seyfettin, Erinmez Muhammet Ali, Unal Mert Cemre, Colak Tamer
Аннотация
BACKGROUND: Pulmonary embolism (PE) is a life-threatening condition characterized by significant morbidity and mortality. Its pathophysiology involves inflammation and stress hyperglycemia. The neutrophil-lymphocyte glycemic index (NLGI) integrates these components to offer a novel prognostic tool.
OBJECTIVES: This study aimed to evaluate the prognostic value of NLGI in predicting in-hospital mortality and major adverse events (MAEs) among patients diagnosed with PE.
METHODS: A retrospective analysis included patients diagnosed with PE using computed tomography pulmonary angiography or ventilation/perfusion scans. Exclusion criteria included chronic PE, diabetes, renal/liver disease, or missing data. NLGI was calculated based on neutrophil count, lymphocyte count, and plasma glucose levels. The primary and secondary outcomes were in-hospital mortality and MAEs, respectively. Logistic regression and receiver operating characteristic (ROC) analyses were performed to assess prognostic performance.
RESULTS: Among 281 patients, in-hospital mortality occurred in 10.3 %, while 17.8 % experienced MAEs. Elevated NLGI was significantly associated with higher mortality and MAEs. Logistic regression confirmed NLGI as an independent predictor of both outcomes. ROC analysis revealed that NLGI showed a higher AUC (0.854) in predicting in-hospital mortality compared to other markers.
CONCLUSIONS: NLGI is a robust, independent predictor of in-hospital mortality and MAEs in PE patients. Its simplicity and strong predictive capability make it a valuable tool for early risk stratification in clinical practice.
OBJECTIVES: This study aimed to evaluate the prognostic value of NLGI in predicting in-hospital mortality and major adverse events (MAEs) among patients diagnosed with PE.
METHODS: A retrospective analysis included patients diagnosed with PE using computed tomography pulmonary angiography or ventilation/perfusion scans. Exclusion criteria included chronic PE, diabetes, renal/liver disease, or missing data. NLGI was calculated based on neutrophil count, lymphocyte count, and plasma glucose levels. The primary and secondary outcomes were in-hospital mortality and MAEs, respectively. Logistic regression and receiver operating characteristic (ROC) analyses were performed to assess prognostic performance.
RESULTS: Among 281 patients, in-hospital mortality occurred in 10.3 %, while 17.8 % experienced MAEs. Elevated NLGI was significantly associated with higher mortality and MAEs. Logistic regression confirmed NLGI as an independent predictor of both outcomes. ROC analysis revealed that NLGI showed a higher AUC (0.854) in predicting in-hospital mortality compared to other markers.
CONCLUSIONS: NLGI is a robust, independent predictor of in-hospital mortality and MAEs in PE patients. Its simplicity and strong predictive capability make it a valuable tool for early risk stratification in clinical practice.